Maung-Maung Thwin

Title: Maung-Maung Thwin: Innovator in Therapeutic Peptides

Introduction

Maung-Maung Thwin is a prominent inventor based in Singapore, known for his significant contributions to the field of therapeutic peptides. He has been awarded 4 patents for his innovative work, particularly in the treatment of inflammatory diseases and cancer.

Latest Patents

His latest patents focus on methods and compositions for the treatment of arthritis and cancer. One notable invention is a new 18-residue homodimerized peptide, designated PIP [59-67] dimer, which is a mutant of the optimized anti-inflammatory peptide P-NT.II. This peptide has the potential to modulate both the inflammatory and bone damaging components of rheumatoid arthritis. The invention utilizes solid phase chemistry to design variants of P-NT.II, which were tested for their inhibitory activity against secretory phospholipase A2 (sPLA2) and matrix metalloproteinases (MMPs). Among the tested mutants, the dimerized peptide emerged as the most potent inhibitor against sPLA2 and human recombinant MMP-1. This invention highlights the utility of the peptide analogue PIP [59-67] dimer as a potential therapeutic agent for inflammatory diseases and cancer.

Career Highlights

Maung-Maung Thwin is affiliated with the National University of Singapore, where he conducts his research and development in therapeutic peptides. His work has garnered attention for its innovative approach to addressing complex medical conditions.

Collaborations

He has collaborated with notable colleagues, including Ponnampalam Gopalakrishnakone and Kandiah Jeyaseelan, to advance research in the field of therapeutic agents.

Conclusion

Maung-Maung Thwin's contributions to the field of therapeutic peptides demonstrate his commitment to innovation in medical science. His work has the potential to significantly impact the treatment of inflammatory diseases and cancer, showcasing the importance of research and development in healthcare.